First liver transplant patients receive experimental drug to prevent hepatitis C infection
Tuesday, January 18, 2011 - 12:31
in Health & Medicine
Following a successful Phase 1 study for safety, researchers at MassBiologics of the University of Massachusetts Medical School (UMMS) today announced the beginning of a Phase 2 clinical trial testing the ability of a human monoclonal antibody they developed to prevent hepatitis C virus (HCV) infection of a donor liver in transplant patients.